Core Viewpoint - WuXi AppTec's revenue from the United States is accelerating, with a projected increase in the share of U.S. revenue to over 52% by the first half of 2025 [1] Financial Performance - In the first half of the year, WuXi AppTec's revenue increased by 62.6% year-on-year, reaching 2.701 billion RMB [1]

8月19日，药明合联CEO李锦才在业绩沟通会上表示，公司来自美国的营收在加速增长。2025年上 半年，该公司来自美国的收入占比突破52%。上半年，药明合联收入同比增长62.6%至27.01亿元人 民币。 ...

Core Viewpoint - WuXi AppTec reported strong H1 performance with revenue of 2.701 billion RMB, a year-on-year increase of 62.2%, and net profit of 746 million RMB, up 52.7%, with a net profit margin of 27.6% [1] Group 1: Financial Performance - Revenue for H1 reached 2.701 billion RMB, reflecting a 62.2% year-on-year growth [1] - Net profit increased to 746 million RMB, representing a 52.7% year-on-year growth [1] - Total uncompleted orders rose to 1.329 billion USD, marking a 57.9% year-on-year increase [1] Group 2: Market Drivers - The growth in H1 performance is attributed to the active development of the global antibody-drug conjugates (ADC) and broader bioconjugates market, leading to an increase in both customer and project numbers [1] - The company's solid position as a leading ADC CRDMO service provider has contributed to an increase in market share [1] - Steady progress of projects into later stages has also supported the growth [1] Group 3: Industry Trends - Recent positive developments in the CXO sector have led to the Hang Seng Medical ETF (159892) reaching a new high [1] - The Hong Kong Stock Connect Medical ETF (520510), which focuses on CXO and AI medical concepts, has seen over a 7% increase since its launch on August 7, with trading prices hitting new highs [1] - The sustained performance of leading companies like WuXi AppTec and WuXi Biologics has boosted market confidence in the CXO sector [1]

Major Events - Double End Co., Ltd. plans to globally offer 58.557 million H-shares from August 18 to August 21, with San Shui Venture Capital as a cornerstone investor [1] - Sunac China intends to issue mandatory convertible bonds and adopt a team stability plan [1] - Ascentage Pharma-B received FDA and EMA approval for the global registration of its Phase III clinical trial for the treatment of high-risk MDS patients [1] - 361 Degrees' subsidiary entered into a strategic cooperation agreement with Stand [1] - Eagle Precision indicates that additional tariffs may impact its business and operations [1] - Green Leaf Pharmaceutical's clinical trial for the treatment of generalized anxiety disorder has completed patient enrollment in China [1] - Tian Tu Investment and HashKey Capital signed a strategic cooperation memorandum to establish a virtual asset investment fund [1] - China Rare Earth Holdings expects annual gold production from MtBundy and Cygnet gold projects to exceed 200,000 ounces [1] Operating Performance - Xinhua Insurance reported a cumulative original insurance premium income of 137.806 billion yuan in the first seven months, a year-on-year increase of 23% [1] - China Biologic Products announced mid-term revenue of 17.57 billion yuan, up 10.7% year-on-year [1] - Meitu Inc. reported a mid-term profit attributable to shareholders of 397 million yuan, a year-on-year increase of 30.84%, with strong growth in MAU and paid subscribers [1] - Xtep International reported a mid-term profit attributable to shareholders of 914 million yuan, a year-on-year increase of 21.47% [1] - Leap Motor achieved a net profit of 33.03 million yuan in the first half of the year, marking its first positive half-year net profit [1] - Hansoh Pharmaceutical reported a mid-term profit attributable to shareholders of 3.135 billion yuan, a year-on-year increase of 15.02% [1] - Kangzheng Pharmaceutical announced a mid-term profit attributable to shareholders of approximately 941 million yuan, a year-on-year growth of 3.38% [1] - Kelun-Bio reported mid-term revenue of 950 million yuan with R&D expenses of 612 million yuan [1] - Sinopec Oilfield Services reported a net profit of approximately 492 million yuan in the first half, a year-on-year increase of 9% [1] - Wanwu Cloud reported a mid-term profit attributable to shareholders of 792 million yuan, a year-on-year increase of 3.88% [1] - Yunfeng Financial expects a significant year-on-year increase of approximately 139% in net profit attributable to equity shareholders, estimated at around 480 million HKD for the first half [1] - United Pharmaceutical anticipates a mid-term net profit of approximately 1.85 billion yuan, a year-on-year increase [1] - Sipai Health reported a mid-term overall gross margin increase of 4.7 percentage points to 14.4% [1] - Orange Sky Golden Harvest expects a net profit attributable to shareholders of no less than 125 million HKD for the first half, marking a turnaround from loss to profit [1] - Baifu Global reported a mid-term profit attributable to shareholders of 391 million HKD, proposing an interim dividend of 0.25 HKD per share [1] - WuXi AppTec reported a mid-term profit attributable to shareholders of 746 million yuan, a year-on-year increase of 52.74% [1] - Joy City Property reported a total contract sales amount of approximately 2.749 billion yuan in the first half, a year-on-year decrease of 81.4% [1]

Financial Performance - Meitu Company (01357.HK) reported a revenue increase of 12.3% year-on-year to RMB 1.8 billion for the six months ending June 30, 2025 [1] - Net profit attributable to equity holders increased by 30.8% year-on-year to RMB 397 million, while adjusted net profit rose by 71.3% to RMB 467 million [1] - Gross profit reached RMB 1.3396 billion, up 27.3% from RMB 1.0526 billion in the same period last year, with a gross margin improvement from 64.9% to 73.6% [1] User Growth - Monthly Active Users (MAU) reached 280 million, reflecting an 8.5% year-on-year growth, which is an improvement from the 6.7% growth recorded in December 2024 [2] - The number of paid subscription users reached approximately 15.4 million, with 13.6 million from lifestyle applications and 1.8 million from productivity tools [2] Product Development - The company launched RoboNeo, an advanced generative AI design assistant, aimed at automating intelligent design to help users create high-quality visual content [2] - The product matrix showed strong growth, with MAU outside mainland China increasing by 15.3% to 98 million, and productivity tools MAU outside mainland China achieving over 90% year-on-year growth [2] Future Outlook - The company plans to continue investing in AI research, particularly in vertical models, to drive product innovation and business growth [2] - The belief is that AI technology will lower the barriers to creative expression, empowering a broader user base [2]

Core Viewpoint - WuXi AppTec (02268) has demonstrated exceptional performance in the bioconjugate drug CRDMO sector, with a revenue growth of 62.2% in the first half of 2025, significantly surpassing annual growth guidance, and achieving a compound annual growth rate (CAGR) of 98% from the first half of 2022 to the first half of 2025, solidifying its leading position in the industry [1][2][4]. Financial Performance - The company's revenue for the first half of 2025 reached 2.701 billion yuan, a year-on-year increase of 62.2%, with a gross profit of 975 million yuan, up 82.2%, and a gross margin of 36.1%, reflecting a 5.5 percentage point increase from the full year of 2024 [2][4]. - Adjusted net profit, excluding interest income and expenses, was 733 million yuan, representing a 69.6% year-on-year growth [2]. Market Position and Growth - WuXi AppTec's market share in the bioconjugate drug CRDMO sector has surged from 9.9% in 2022 to approximately 22% in the first half of 2025, indicating strong market penetration and growth [7][11]. - The company signed a record 37 new iCMC projects in the first half of 2025, with a focus on innovative ADC molecules, including bispecific ADCs and multi-load ADCs [4][12]. Client Engagement and International Expansion - The number of global clients increased to 563, with 64 new clients added in the first half of 2025, including 13 of the top 20 global pharmaceutical companies [4][11]. - Approximately 82% of the company's revenue in the first half of 2025 came from international markets, highlighting its role as a preferred partner for overseas pharmaceutical companies [11]. Production Capacity and Infrastructure - The new DP3 production facility in Wuxi has been successfully GMP released, with an annual capacity of 7 million bottles, increasing the overall DP capacity to 15 million bottles [15][19]. - The company is also advancing its global strategy with a new production base in Singapore, expected to achieve GMP release by the first half of 2026 [19][22]. Technological Advancements - WuXi AppTec has made significant investments in technology, launching new payload linker technologies, WuXiTecan-1 and WuXiTecan-2, to enhance its service offerings [29]. - The company has advanced 1,000 molecules in early research for XDC, with a focus on high-difficulty ADC types, ensuring a robust pipeline for future growth [25][29]. Conclusion - WuXi AppTec's strong project reserves, efficient capacity construction, and strategic focus on innovative ADC and bioconjugate drug development position it as a leader in the CRDMO sector, driving sustained high growth [32].

Core Viewpoint - WuXi AppTec (02268) has demonstrated exceptional performance in the bioconjugate drug CRDMO sector, with a revenue growth of 62.2% in the first half of 2025, significantly surpassing annual growth guidance, and achieving a compound annual growth rate (CAGR) of 98% from the first half of 2022 to the first half of 2025, solidifying its leading position in the industry [1][2][4]. Financial Performance - The company's revenue for the first half of 2025 reached 2.701 billion yuan, a year-on-year increase of 62.2%, with a nearly doubled revenue growth in the non-ADC segment [2]. - Gross profit amounted to 975 million yuan, reflecting an 82.2% increase, while the gross margin rose to 36.1%, up by 5.5 percentage points compared to the full year of 2024 [2]. - Adjusted net profit, excluding interest income and expenses, reached 733 million yuan, marking a 69.6% year-on-year growth [2]. Project Development - In the first half of 2025, the company signed a record 37 new iCMC projects, indicating both quantity and quality improvements, with innovative ADC molecules such as bispecific ADCs and dual payload ADCs frequently appearing [3][12]. - The company added 3 new PPQ projects and successfully completed 4 component production executions in the PPQ phase, laying a solid foundation for future commercialization [3][14]. - The number of global clients increased to 563, with 64 new clients added in the first half of the year, including 13 out of the top 20 global pharmaceutical companies [3][11]. Market Position and Strategy - WuXi AppTec's market share in the bioconjugate drug CRDMO sector has surged from 9.9% in 2022 to approximately 22% in the first half of 2025, driven by strong demand for high-value innovative technologies [4][11]. - The company has become a preferred partner for overseas pharmaceutical companies, with approximately 82% of its revenue coming from international markets in the first half of 2025 [11]. - The company is recognized for its dual approach of empowering clients and maintaining high-quality service, which has led to a significant share of ADC mergers and acquisitions involving its clients [11]. Capacity Expansion - The company’s new DP3 production facility in Wuxi has completed GMP release, with an annual capacity of 7 million bottles, increasing the overall DP capacity to 15 million bottles [15]. - The construction of the DP5 facility has commenced, with plans for GMP production by 2027, further strengthening the company’s competitive edge in the CRDMO sector [15][22]. - WuXi AppTec is committed to continuous investment in capacity expansion, with capital expenditures expected to exceed 7 billion yuan by 2029 [22]. Technological Innovation - The company has advanced its capabilities in early research, progressing 1,000 molecules in the XDC early research area and completing approximately 90 bispecific ADC types and 40 dual payload ADC types [25][29]. - New payload linker technologies, WuXiTecan-1 and WuXiTecan-2, have been introduced, enhancing the company's technological toolbox for clients [29]. - The company’s strategic focus on high-value areas such as bispecific ADCs and dual payload ADCs positions it well for future growth in the bioconjugate drug market [32].

Group 1 - The company reported a revenue of RMB 2.7 billion for the six months ending June 30, 2025, representing a year-on-year increase of 62.19% [1] - The net profit attributable to the company's owners was RMB 746 million, an increase of 52.74% year-on-year, with basic earnings per share of RMB 0.62 [1] - The revenue growth was driven by the active development of the global antibody-drug conjugate (ADC) and broader bioconjugate markets, leading to an increase in both customer and project numbers [1] Group 2 - The CRDMO business showed strong momentum in the first half of 2025, with increasing global demand for its services, having empowered a total of 563 global clients [2] - The company has successfully secured 11 process validation (PPQ) projects and one commercial stage project [2] - The company has been recognized as the "Best CDMO" at the World ADC awards for 2023 and 2024, highlighting its leading position in providing technology-driven comprehensive services for ADCs and bioconjugates [2] Group 3 - The company is expanding its production capacity and attracting talent to prepare for the growing demand for bioconjugate CRDMO services [2] - The GMP release of the XDP3 formulation workshop and the expansion of the Wuxi base, including the ongoing construction of the XDP5 formulation workshop, are progressing as planned [2] - The completion of these expansions will provide additional monoclonal antibody, drug substance (DS), and drug product (DP) production lines, laboratories, and office space [2]

Core Insights - WuXi AppTec (02268) reported a revenue of RMB 2.7 billion for the six months ending June 30, 2025, representing a year-on-year increase of 62.19% [1] - The net profit attributable to the company's owners was RMB 746 million, up 52.74% year-on-year, with basic earnings per share of RMB 0.62 [1] - The revenue growth was driven by the active development of the global antibody-drug conjugates (ADC) and broader bioconjugates market, leading to an increase in both client and project numbers [1] Group Performance - The CRDMO business exhibited strong momentum in the first half of 2025, with a continuous positive expansion and increased global demand for its services [2] - As of June 30, 2025, the company has empowered a total of 563 global clients through its comprehensive CRDMO capabilities and "one-stop" facilities from drug discovery to commercialization [2] - The company has successfully secured 11 PPQ (Process Performance Qualification) projects and one commercial stage project [2] Industry Recognition - The company was awarded the "Best CDMO" title by World ADC for 2023 and 2024, highlighting its excellence in providing technology-driven comprehensive services for ADCs and broader bioconjugates [2] - The company continues to enhance its production capacity and attract talent to prepare for expanding its market share and meet the growing global demand for bioconjugate CRDMO services [2] - Ongoing projects include the GMP release of the XDP3 formulation workshop, expansion of the Wuxi base, and the construction of a new facility in Singapore, which will increase production lines and laboratory space upon completion [2]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 WUXI XDC CAYMAN INC. （於開曼群島註冊成立的有限公司） 藥 明 合 聯 生 物 技 術 有 限 公 司* （股份代號：2268） 內幕消息 2025年中期業績簡報 本公 告由藥 明合 聯生物 技術有 限公司 *（「本 公司」）根據香 港聯 合交易 所有限 公司 證 券 上 市 規 則（「 上 市 規 則 」）第 13.09 條 以 及 香 港 法 例 第 571 章 證 券 及 期 貨 條 例 第 XIVA部項下的內幕消息條文（ 定義見上市規則 ）而刊發。 為使本公司股東及有意投資者能夠更深入、更全面地了解其2025年中期業績及業 務 營 運 ， 本 公 司 將 於 2025 年 8 月 19 日 上 午 八 時 三 十 分 及 下 午 八 時 三 十 分（ 香 港 時 間 ）召 開 電 話 會 議 ， 屆 時 將 就 ...